Genzyme's Clolar Treatment Priced At $90,000 For An Average Patient
This article was originally published in The Pink Sheet Daily
Executive Summary
Clofarabine carries an average wholesale price of $2,812.50 per 20 mL vial, according to Medi-Span's Price Alert. Assuming no rebates, annual revenues for the product could be in the range of $45 mil.-$90 mil.
You may also be interested in...
Genzyme Clolar Approved For Pediatric Acute Lymphoblastic Leukemia
Indication follows advisory committee recommendation to approve clofarabine for ALL but not for pediatric acute myelogenous leukemia. Genzyme will have to redesign its confirmatory trial within two months.
Avastin, Erbitux Prices Invite Price Controls, Former NCI Deputy Says In Editorial
The prices set by Genentech and Bristol-Myers Squibb for their recently launched colorectal cancer therapies are an invitation to impose price controls, former Memorial-Sloan Kettering Cancer Center Physician-in-Chief Robert Wittes, MD, wrote in an editorial published by the Washington Post June 15
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.